Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at Jefferies Group cut their Q3 2016 earnings per share estimates for Sarepta Therapeutics in a research note issued on Monday. Jefferies Group analyst G. Wang now anticipates that the brokerage will earn ($1.38) per share for the quarter, down from their prior estimate of ($1.31). Jefferies Group currently has a “Hold” rating and a $50.00 target price on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($0.51) EPS, FY2016 earnings at ($4.51) EPS, FY2017 earnings at ($2.90) EPS, FY2018 earnings at ($0.15) EPS, FY2019 earnings at $2.49 EPS and FY2020 earnings at $3.89 EPS.

SRPT has been the topic of a number of other reports. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 target price on the stock in a research note on Thursday, June 2nd. RBC Capital Markets upgraded shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research note on Monday. William Blair reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Finally, Needham & Company LLC raised their target price on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.68% during midday trading on Wednesday, reaching $56.11. 5,095,164 shares of the company traded hands. The firm’s 50 day moving average price is $28.17 and its 200 day moving average price is $21.37. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $58.87. The firm’s market capitalization is $2.69 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/q3-2016-eps-estimates-for-sarepta-therapeutics-inc-decreased-by-analyst-srpt.html

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the business posted ($0.87) EPS.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the last quarter. State Street Corp boosted its stake in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $13,506,000. 72.09% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.